SCOPUS 정보 검색 플랫폼

Endocrine Practice

Volumn 8, Issue 6, 2002, Pages 406-410

Lipoprotein effects of different thiazolidinediones in clinical practice

(2) Ovalle, Fernando a Bell, David S H a

a University of Alabama at Birmingham (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 0036857542 PISSN: 1530891X EISSN: None Source Type: Journal
DOI: 10.4158/ep.8.6.406 Document Type: Article

Times cited : (25)

References (8)

1
- 0029995670
- Thiazolidinediones in the treatment of insulin resistance in type II diabetes
- Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance in type II diabetes. Diabetes. 1996;45:1661-1669.
- (1996) Diabetes , vol.45 , pp. 1661-1669
- Saltiel, A.R.¹ Olefsky, J.M.²

2
- 0035793135
- Nonhypoglycemic effects of thiazolidinediones
- [erratum in Ann Intern Med. 2001;135:307]
- Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones [erratum in Ann Intern Med. 2001;135:307]. Ann Intern Med. 2001;134:61-71.
- (2001) Ann. Intern. Med. , vol.134 , pp. 61-71
- Parulkar, A.A.¹ Pendergrass, M.L.² Granda-Ayala, R.³ Lee, T.R.⁴ Fonseca, V.A.⁵

3
- 0028078733
- Quantification of cholesterol in all lipoprotein classes by the VAP-II method
- Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res. 1994;35:159-168.
- (1994) J. Lipid Res. , vol.35 , pp. 159-168
- Kulkarni, K.R.¹ Garber, D.W.² Marcovina, S.M.³ Segrest, J.P.⁴

4
- 0034700641
- The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review
- Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol. 2000;86(12A):5L-10L.
- (2000) Am. J. Cardiol. , vol.86 , Issue.12 A
- Kwiterovich P.O., Jr.¹

5
- 0032913707
- Dyslipidemia of central obesity and insulin resistance
- Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22(Suppl 3):C10-C13.
- (1999) Diabetes Care , vol.22 , Issue.SUPPL. 3
- Brunzell, J.D.¹ Hokanson, J.E.²

6
- 0031736142
- Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
- Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 1998;21:796-799.
- (1998) Diabetes Care , vol.21 , pp. 796-799
- Tack, C.J.¹ Smits, P.² Demacker, P.N.³ Stalenhoef, A.F.⁴

7
- 0000396919
- Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes
- Brunzell J, Cohen BR, Kreider M, et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes. 2001;50(Suppl 2):A141.
- (2001) Diabetes , vol.50 , Issue.SUPPL. 2
- Brunzell, J.¹ Cohen, B.R.² Kreider, M.³

8
- 0034900336
- Conversion from troglitazone to rosiglitazone
- [letter]
- Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone [letter]. Endocr Pract. 2001; 7:326.
- (2001) Endocr. Pract. , vol.7 , pp. 326
- Bell, D.S.H.¹ Ovalle, F.² Shadmany, S.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.